Skip to content
Austin Top 50
Author:
Mondego Bio
Mondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer Immunotherapy
November 5, 2026